Swiss Pharma Faces Potential US Section 301 Trade Investigation Over Drug Pricing Policies
核心洞察
The United States could open a Section 301 trade investigation into Switzerland's pharmaceutical industry, following a similar probe launched against Germany, according to Interpharma (搜索) CEO René Buholzer.
Republican lawmakers have named both Germany and Switzerland as countries "doubling down" on strategies that unfairly shift the burden of pharmaceutical innovation costs onto US consumers.
Switzerland is currently reviewing measures to reduce mandatory healthcare prices, which could lower drug prices and has drawn criticism from the pharmaceutical industry.
Switzerland's pharmaceutical industry could become the next target of a US trade investigation, the head of Swiss industry body Interpharma (搜索) warned on Friday, as Washington intensifies scrutiny of foreign drug pricing policies it considers unfair to American commerce.
René Buholzer, CEO of Interpharma (搜索), said in a statement that "it is clear that Switzerland is also a potential target in light of the current (health insurance ordinance) revision." The warning comes just eight days after the United States launched a formal Section 301 investigation into Germany over similar concerns.
The Section 301 trade mechanism allows the US administration to investigate foreign practices deemed unfair and, where findings warrant, impose tariffs on imports from the country under scrutiny. Public hearings on the German investigation are scheduled for 22 September 2026.
Political Pressure Mounts
Buholzer pointed to a letter written by Republican US congressmen this month urging the US Trade Representative and commerce secretary to open Section 301 investigations into unfair foreign pharmaceutical pricing policies. The lawmakers argued that foreign governments' spending curbs unfairly push the burden of pharmaceutical innovation onto US consumers, and named both Germany and Switzerland as "doubling down on their strategy to free-ride off the United States."
Switzerland is currently reviewing measures aimed at reducing mandatory healthcare prices, which could see drug prices lowered — a move the industry has criticised. The ongoing revisions to Swiss health insurance ordinances are seen as a contributing factor to Washington's concerns.
Economic Stakes
The stakes for Switzerland are substantial. Pharmaceutical and chemical products made up over half of the country's exports last year. Switzerland is home to major drugmakers including Roche and Novartis, with approximately US$35.5 billion in annual pharmaceutical shipments destined for the American market.
The US has previously threatened average tariffs of 39% on Swiss goods, though pharmaceutical products have been separately capped at 15% under prior agreements. Even at the capped rate, such tariffs would represent a significant financial burden on the export volume.
Industry Response and Broader Context
Washington's broader trade strategy centres on the argument that American patients pay disproportionately more for prescription drugs than those in other developed nations, effectively subsidising lower drug prices abroad. Switzerland's position is complicated by its own domestic healthcare cost reforms, which were designed to adjust drug pricing and reimbursement ordinances with Swiss patients and budgets in mind, not to satisfy US trade negotiators.
Both Roche and Novartis have historically responded to American trade pressure by pledging increased investment and manufacturing on US soil — a playbook analysts expect both companies to deploy again if a formal investigation is initiated.
The investigation into Germany was triggered after Berlin unveiled plans in April for a wide-ranging overhaul of its statutory healthcare system, including plans to lower spending on pharmaceutical products. That probe could result in the US taking tariff-related action against German imports, though sources have since indicated the German government is backtracking on the plan following opposition from pharmaceutical companies.